FDA stops pain drug trial over safety concerns

NewsGuard 100/100 Score

Johnson & Johnson revealed Tuesday this week that a clinical trial of its experimental pain drug, fulranumab, has been stopped after the Food and Drug Administration expressed concerns that patients taking the drug could suffer increased joint damage.

Fulranumab belongs to a class of drugs called nerve growth factor inhibitors that block osteoarthritis pain by reducing a protein linked to the condition. Osteoarthritis is a chronic disease and leads to the eventual loss of cartilage in the joints.

However the FDA has investigated reports that some patients treated with the drugs could suffer from rapidly progressive osteoarthritis, a wearing away of the cartilage protecting bone joints, or osteonecrosis, the death of bone tissue due to a lack of blood supply.

The FDA’s intervention also stopped AstraZeneca PLC's Medimmune unit’s drug MEDI-578 in July after Pfizer Inc. stopped a similar trial. Pfizer had halted studies of its drug, tanezumab, at the request of the FDA. Regeneron Pharmaceuticals Inc. and Sanofi-Aventis SA disclosed this Monday that they had also halted a study of their inhibitor drug after being contacted by the FDA. The extent of injuries to the patients is not known yet.

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2018, August 23). FDA stops pain drug trial over safety concerns. News-Medical. Retrieved on May 23, 2024 from https://www.news-medical.net/news/20101229/FDA-stops-pain-drug-trial-over-safety-concerns.aspx.

  • MLA

    Mandal, Ananya. "FDA stops pain drug trial over safety concerns". News-Medical. 23 May 2024. <https://www.news-medical.net/news/20101229/FDA-stops-pain-drug-trial-over-safety-concerns.aspx>.

  • Chicago

    Mandal, Ananya. "FDA stops pain drug trial over safety concerns". News-Medical. https://www.news-medical.net/news/20101229/FDA-stops-pain-drug-trial-over-safety-concerns.aspx. (accessed May 23, 2024).

  • Harvard

    Mandal, Ananya. 2018. FDA stops pain drug trial over safety concerns. News-Medical, viewed 23 May 2024, https://www.news-medical.net/news/20101229/FDA-stops-pain-drug-trial-over-safety-concerns.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Caffeine vs. creatine: The impact on cognitive and physical performances